NFKB1 and breast carcinoma: Since our results show that NFKB1 binds to the E5 constituent enhancer within the breast cancer CD47 SE, we hypothesized that in breast cancer cells, CD47 expression could be reduced when disrupting the CD47 SE enhancing function by blocking the binding of BRD4 to SEs with the JQ1 inhibitor29.